Launched by PureTech and backed by well-known venture capital firms, the startup has raised $325 million since its debut this spring.

Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance taking a minority 2% position.

Immunotherapy and precision medicine show promise in better fighting cancer. What else does the research tell us?

The Fortis Life Sciences team will be presenting two posters on Friday, November 8, 2024 in the George R. Brown Convention Center, Level 1 – Exhibit Halls AB.

ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry and a portfolio company of Odyssey Investment Partners, today announced that ...

To enhance patient outcomes and increased trial success, Convert Pharma is leveraging companion AI- and genetic biomarkers, a ...

The amount surpassed the firm’s targets, allowing it to increase the size and number of company financings it plans to do in the future.

Vyalev’s clearance is the second victory for AbbVie in Parkinson’s this year, following an April readout for a drug acquired through its Cerevel buyout.

The hold, which was made in response to a serious adverse event report, could impact the company’s plans to start a Phase 3 trial of a combination shot for COVID-19 and influenza.

The lawsuit focuses on scientific work that helped clear the path for creating mRNA vaccines to fight the COVID-19 pandemic.

The pharma will work with Triana Biomedicines on molecular glue degraders. Elsewhere, Akeso raised $250 million and a MASH drug developer got a well-known board chair.

The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in ...